• LAST PRICE
    0.0010
  • TODAY'S CHANGE (%)
    Trending Down0.0000 (-5.0000%)
  • Bid / Lots
    0.0009/ 100
  • Ask / Lots
    0.0010/ 41,286
  • Open / Previous Close
    0.0010 / 0.0010
  • Day Range
    Low 0.0009
    High 0.0010
  • 52 Week Range
    Low 0.0006
    High 0.0191
  • Volume
    1,171,909
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 0.001
TimeVolumeRSPI
09:32 ET774000.001
11:27 ET10000000.0009
11:42 ET500000.00095
11:47 ET200000.00095
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesRSPI
RespireRx Pharmaceuticals Inc
365.4K
-0.1x
---
United StatesMYRX
Myrexis Inc
362.0K
0.0x
---
United StatesLIFS
Life Stem Genetics Inc
368.8K
-0.1x
---
United StatesRNAZ
Transcode Therapeutics Inc
426.0K
0.0x
---
United StatesPHBI
Pharmagreen Biotech Inc
431.4K
-0.5x
---
United StatesXSNX
NovAccess Global Inc
224.7K
-0.1x
---
As of 2024-03-28

Company Information

RespireRx Pharmaceuticals Inc. develops treatments to combat disorders caused by disruption of neuronal signaling. The Company is developing treatment options that address conditions, such as obstructive sleep apnea (OSA), attention deficit hyperactivity disorder, epilepsy, acute and chronic pain, including inflammatory and neuropathic pain, and recovery from spinal cord injury (SCI), which are conditions that affect millions of people, as well as certain orphan disorders such as GRIA. It also considers developing treatment options for other conditions based on results of preclinical and clinical studies to date. The Company has two business units. ResolutionRx unit holds its pharmaceutical cannabinoids platform, and is developing compounds that target the body’s endocannabinoid system, and in particular, the re-purposing of dronabinol for the treatment of OSA. EndeavourRx is its neuromodulators platform, which is made up of two programs: AMPAkines program and GABAkines program.

Contact Information

Headquarters
126 Valley Rd Ste CGLEN ROCK, NJ, United States 07452-1796
Phone
201-444-4947
Fax
302-652-6760

Executives

Executive Chairman of the Board, Interim President, Interim Chief Executive Officer, Chief Scientific Officer
Arnold Lippa
Chief Financial Officer, Senior Vice President, Treasurer, Secretary, Director
Jeff Margolis
Senior Vice President - Pre-Clinical Product Development
David Dickason
Senior Vice President - Research and Development
Richard Purcell
Director
Dariusz Nasiek

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$365.4K
Revenue (TTM)
$0.00
Shares Outstanding
365.4M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.51
EPS
$-0.01
Book Value
$-0.09
P/E Ratio
-0.1x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.